Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Inflammatory Bowel Diseases | 85 | 2024 | 2422 | 12.590 |
Why?
|
Crohn Disease | 76 | 2024 | 2279 | 9.450 |
Why?
|
Drug Monitoring | 36 | 2024 | 962 | 8.850 |
Why?
|
Gastrointestinal Agents | 38 | 2024 | 510 | 7.710 |
Why?
|
Colitis, Ulcerative | 51 | 2024 | 1922 | 5.340 |
Why?
|
Tumor Necrosis Factor-alpha | 36 | 2023 | 4352 | 4.290 |
Why?
|
Biological Products | 14 | 2024 | 914 | 3.020 |
Why?
|
Azathioprine | 8 | 2022 | 354 | 2.450 |
Why?
|
Colonoscopy | 14 | 2020 | 1394 | 2.090 |
Why?
|
Antibodies, Monoclonal | 30 | 2024 | 9177 | 1.970 |
Why?
|
Colitis | 9 | 2022 | 1233 | 1.760 |
Why?
|
Immunosuppressive Agents | 15 | 2022 | 4174 | 1.700 |
Why?
|
Remission Induction | 18 | 2024 | 2396 | 1.680 |
Why?
|
Practice Guidelines as Topic | 14 | 2021 | 7390 | 1.540 |
Why?
|
Immunologic Factors | 13 | 2024 | 1589 | 1.500 |
Why?
|
Capsule Endoscopy | 6 | 2021 | 100 | 1.280 |
Why?
|
Anti-Inflammatory Agents | 8 | 2024 | 1809 | 1.090 |
Why?
|
Mesalamine | 9 | 2016 | 135 | 1.060 |
Why?
|
Gastroenterology | 5 | 2021 | 577 | 1.050 |
Why?
|
Guideline Adherence | 5 | 2020 | 2220 | 1.010 |
Why?
|
Conflict of Interest | 6 | 2016 | 554 | 1.010 |
Why?
|
Serum | 3 | 2017 | 209 | 0.980 |
Why?
|
Evidence-Based Medicine | 7 | 2016 | 3688 | 0.960 |
Why?
|
Endoscopy, Gastrointestinal | 5 | 2023 | 874 | 0.900 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 14 | 2016 | 2273 | 0.870 |
Why?
|
Medical Records | 4 | 2017 | 1408 | 0.860 |
Why?
|
Bronchial Diseases | 2 | 2014 | 150 | 0.850 |
Why?
|
Standard of Care | 4 | 2022 | 551 | 0.840 |
Why?
|
Humans | 197 | 2024 | 761504 | 0.820 |
Why?
|
Rectal Fistula | 2 | 2024 | 75 | 0.780 |
Why?
|
Sickness Impact Profile | 2 | 2013 | 299 | 0.780 |
Why?
|
Pulmonary Medicine | 2 | 2014 | 221 | 0.780 |
Why?
|
Documentation | 3 | 2017 | 897 | 0.760 |
Why?
|
Colectomy | 3 | 2015 | 688 | 0.740 |
Why?
|
Intestinal Fistula | 1 | 2021 | 142 | 0.700 |
Why?
|
Nephrology | 2 | 2014 | 263 | 0.700 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 312 | 0.690 |
Why?
|
Calculi | 1 | 2019 | 48 | 0.650 |
Why?
|
Fertilization in Vitro | 3 | 2016 | 1292 | 0.640 |
Why?
|
Triage | 2 | 2015 | 986 | 0.610 |
Why?
|
Hepatitis B Core Antigens | 1 | 2018 | 90 | 0.600 |
Why?
|
Hepatitis B Antibodies | 1 | 2018 | 155 | 0.580 |
Why?
|
Irritable Bowel Syndrome | 2 | 2013 | 455 | 0.570 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2018 | 294 | 0.550 |
Why?
|
Coloring Agents | 1 | 2019 | 562 | 0.540 |
Why?
|
Diarrhea | 3 | 2017 | 1318 | 0.540 |
Why?
|
Hepatitis B virus | 2 | 2018 | 528 | 0.540 |
Why?
|
Drug Tolerance | 2 | 2018 | 367 | 0.540 |
Why?
|
Adult | 74 | 2024 | 221177 | 0.540 |
Why?
|
Colonic Neoplasms | 5 | 2020 | 2538 | 0.540 |
Why?
|
Light | 2 | 2020 | 1353 | 0.540 |
Why?
|
Arthritis, Psoriatic | 1 | 2019 | 219 | 0.530 |
Why?
|
Immunocompromised Host | 2 | 2012 | 856 | 0.530 |
Why?
|
Virus Activation | 1 | 2018 | 322 | 0.520 |
Why?
|
Helicobacter pylori | 1 | 2019 | 377 | 0.520 |
Why?
|
Helicobacter Infections | 1 | 2019 | 388 | 0.520 |
Why?
|
Cannabis | 1 | 2021 | 441 | 0.500 |
Why?
|
Middle Aged | 65 | 2024 | 220895 | 0.490 |
Why?
|
Disease Management | 6 | 2021 | 2508 | 0.490 |
Why?
|
Male | 87 | 2024 | 360804 | 0.480 |
Why?
|
C-Reactive Protein | 8 | 2024 | 3826 | 0.480 |
Why?
|
Apyrase | 5 | 2020 | 373 | 0.480 |
Why?
|
Obstetric Labor Complications | 1 | 2017 | 236 | 0.480 |
Why?
|
Complementary Therapies | 2 | 2016 | 486 | 0.460 |
Why?
|
Infertility | 3 | 2016 | 654 | 0.460 |
Why?
|
Female | 89 | 2024 | 392644 | 0.460 |
Why?
|
Therapeutic Irrigation | 2 | 2014 | 292 | 0.450 |
Why?
|
Herpesvirus 3, Human | 2 | 2012 | 159 | 0.440 |
Why?
|
Intestine, Small | 4 | 2013 | 1206 | 0.430 |
Why?
|
Pouchitis | 3 | 2022 | 64 | 0.430 |
Why?
|
Emergency Service, Hospital | 4 | 2018 | 7879 | 0.430 |
Why?
|
Treatment Outcome | 30 | 2024 | 64680 | 0.410 |
Why?
|
Intestinal Obstruction | 2 | 2006 | 432 | 0.410 |
Why?
|
Mycobacterium marinum | 1 | 2012 | 29 | 0.410 |
Why?
|
Barrett Esophagus | 1 | 2016 | 492 | 0.400 |
Why?
|
Coronary Angiography | 2 | 2014 | 4471 | 0.400 |
Why?
|
Antirheumatic Agents | 2 | 2012 | 1372 | 0.400 |
Why?
|
Treatment Failure | 5 | 2019 | 2645 | 0.400 |
Why?
|
Herpes Zoster | 2 | 2012 | 253 | 0.390 |
Why?
|
Skin Diseases, Bacterial | 1 | 2012 | 68 | 0.390 |
Why?
|
Chickenpox | 1 | 2012 | 96 | 0.380 |
Why?
|
Drug Evaluation | 1 | 2012 | 641 | 0.380 |
Why?
|
Mycophenolic Acid | 1 | 2013 | 348 | 0.380 |
Why?
|
Cryptosporidium | 1 | 2011 | 41 | 0.380 |
Why?
|
Cannabinoids | 1 | 2013 | 172 | 0.380 |
Why?
|
Cryptosporidiosis | 1 | 2011 | 52 | 0.370 |
Why?
|
Comparative Effectiveness Research | 3 | 2020 | 709 | 0.370 |
Why?
|
Cyclosporine | 2 | 2011 | 778 | 0.370 |
Why?
|
Th17 Cells | 5 | 2022 | 794 | 0.370 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 1089 | 0.370 |
Why?
|
Drug Hypersensitivity | 2 | 2014 | 917 | 0.360 |
Why?
|
Capsule Endoscopes | 2 | 2009 | 13 | 0.360 |
Why?
|
Arthritis, Rheumatoid | 2 | 2019 | 3763 | 0.360 |
Why?
|
Medication Adherence | 5 | 2015 | 2176 | 0.350 |
Why?
|
Adrenal Cortex Hormones | 4 | 2014 | 1880 | 0.340 |
Why?
|
Iatrogenic Disease | 1 | 2013 | 539 | 0.340 |
Why?
|
Infertility, Female | 1 | 2016 | 760 | 0.340 |
Why?
|
Tomography, X-Ray Computed | 5 | 2016 | 20570 | 0.340 |
Why?
|
Delivery, Obstetric | 1 | 2017 | 940 | 0.340 |
Why?
|
Osteoporosis | 1 | 2019 | 1606 | 0.340 |
Why?
|
Retrospective Studies | 26 | 2024 | 80636 | 0.340 |
Why?
|
Vaccines, Attenuated | 1 | 2011 | 315 | 0.330 |
Why?
|
Opportunistic Infections | 1 | 2012 | 376 | 0.330 |
Why?
|
Cellulitis | 1 | 2011 | 209 | 0.330 |
Why?
|
Colonic Polyps | 1 | 2014 | 554 | 0.330 |
Why?
|
Immunomodulation | 1 | 2013 | 549 | 0.320 |
Why?
|
Health Priorities | 1 | 2012 | 374 | 0.320 |
Why?
|
Attitude of Health Personnel | 3 | 2021 | 3889 | 0.310 |
Why?
|
Tumor Necrosis Factors | 2 | 2019 | 107 | 0.310 |
Why?
|
Drug Substitution | 2 | 2021 | 290 | 0.310 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2020 | 4016 | 0.310 |
Why?
|
Research Support as Topic | 1 | 2012 | 697 | 0.310 |
Why?
|
Young Adult | 27 | 2024 | 59243 | 0.310 |
Why?
|
Cesarean Section | 1 | 2017 | 1396 | 0.300 |
Why?
|
Potentilla | 1 | 2007 | 1 | 0.300 |
Why?
|
Infusions, Parenteral | 1 | 2008 | 397 | 0.300 |
Why?
|
Patient Care | 1 | 2013 | 622 | 0.300 |
Why?
|
Congenital Abnormalities | 1 | 2013 | 709 | 0.290 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2020 | 10766 | 0.280 |
Why?
|
Cytomegalovirus Infections | 1 | 2013 | 831 | 0.280 |
Why?
|
Endoscopes, Gastrointestinal | 1 | 2006 | 45 | 0.270 |
Why?
|
Adenoma | 2 | 2014 | 2160 | 0.270 |
Why?
|
Colon | 5 | 2017 | 1792 | 0.270 |
Why?
|
Lichen Planus, Oral | 1 | 2007 | 57 | 0.270 |
Why?
|
Colorectal Neoplasms | 3 | 2014 | 6935 | 0.260 |
Why?
|
Hepatitis B | 1 | 2011 | 705 | 0.260 |
Why?
|
Antigens, CD | 4 | 2020 | 4003 | 0.260 |
Why?
|
Private Practice | 2 | 2017 | 153 | 0.260 |
Why?
|
Education, Medical | 1 | 2017 | 1725 | 0.260 |
Why?
|
Clinical Protocols | 3 | 2009 | 1440 | 0.260 |
Why?
|
Skin Diseases | 1 | 2014 | 1094 | 0.250 |
Why?
|
Severity of Illness Index | 12 | 2023 | 15842 | 0.250 |
Why?
|
Ambulatory Care | 2 | 2015 | 2775 | 0.250 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 4 | 2020 | 3810 | 0.240 |
Why?
|
Prospective Studies | 19 | 2023 | 54425 | 0.240 |
Why?
|
Quality Indicators, Health Care | 1 | 2014 | 1792 | 0.240 |
Why?
|
Prognosis | 15 | 2023 | 29625 | 0.230 |
Why?
|
Digestive System Surgical Procedures | 1 | 2009 | 572 | 0.230 |
Why?
|
Leukocyte L1 Antigen Complex | 1 | 2024 | 93 | 0.230 |
Why?
|
Plant Extracts | 1 | 2007 | 498 | 0.220 |
Why?
|
Endoscopy | 4 | 2020 | 1851 | 0.220 |
Why?
|
Infusions, Intravenous | 4 | 2014 | 2219 | 0.220 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2022 | 10209 | 0.220 |
Why?
|
Mucous Membrane | 3 | 2023 | 659 | 0.220 |
Why?
|
Colonic Pouches | 3 | 2016 | 122 | 0.210 |
Why?
|
Biological Therapy | 1 | 2024 | 141 | 0.210 |
Why?
|
Delphi Technique | 3 | 2021 | 846 | 0.200 |
Why?
|
Hypersensitivity, Immediate | 1 | 2005 | 347 | 0.200 |
Why?
|
Ileitis | 1 | 2022 | 39 | 0.200 |
Why?
|
Autoimmune Diseases | 1 | 2014 | 2244 | 0.200 |
Why?
|
Antibodies | 3 | 2023 | 2418 | 0.200 |
Why?
|
Cohort Studies | 12 | 2020 | 41487 | 0.190 |
Why?
|
Physicians | 2 | 2017 | 4591 | 0.190 |
Why?
|
Odds Ratio | 5 | 2020 | 9646 | 0.190 |
Why?
|
Consensus | 4 | 2021 | 3123 | 0.190 |
Why?
|
Time Factors | 10 | 2024 | 39967 | 0.190 |
Why?
|
Patient Readmission | 1 | 2015 | 3270 | 0.190 |
Why?
|
Predictive Value of Tests | 6 | 2018 | 15266 | 0.180 |
Why?
|
Hospitalization | 4 | 2018 | 10723 | 0.180 |
Why?
|
Probiotics | 3 | 2016 | 378 | 0.180 |
Why?
|
Pregnancy Complications | 2 | 2013 | 2947 | 0.180 |
Why?
|
Adolescent | 14 | 2023 | 88319 | 0.180 |
Why?
|
Wound Healing | 4 | 2024 | 2805 | 0.180 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1866 | 0.180 |
Why?
|
Research Design | 2 | 2015 | 6180 | 0.180 |
Why?
|
RNA, Antisense | 1 | 2020 | 136 | 0.180 |
Why?
|
Societies, Medical | 5 | 2021 | 3905 | 0.170 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2020 | 364 | 0.170 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2022 | 779 | 0.170 |
Why?
|
Early Detection of Cancer | 3 | 2020 | 3201 | 0.170 |
Why?
|
Disclosure | 3 | 2015 | 748 | 0.170 |
Why?
|
Intestinal Mucosa | 5 | 2021 | 3032 | 0.170 |
Why?
|
Interleukins | 1 | 2024 | 782 | 0.160 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2019 | 293 | 0.160 |
Why?
|
Health Services Research | 2 | 2017 | 1812 | 0.160 |
Why?
|
Follow-Up Studies | 16 | 2018 | 39106 | 0.160 |
Why?
|
Nitroimidazoles | 2 | 2010 | 117 | 0.160 |
Why?
|
Tuberculosis | 1 | 2011 | 2017 | 0.160 |
Why?
|
Diagnosis, Differential | 6 | 2013 | 12974 | 0.150 |
Why?
|
Vaccination | 1 | 2011 | 3384 | 0.150 |
Why?
|
Anticoagulants | 1 | 2014 | 4812 | 0.150 |
Why?
|
Sentinel Surveillance | 1 | 2020 | 291 | 0.150 |
Why?
|
Intra-Abdominal Fat | 1 | 2023 | 613 | 0.150 |
Why?
|
Recurrence | 6 | 2020 | 8465 | 0.150 |
Why?
|
Sexually Transmitted Diseases | 1 | 2024 | 662 | 0.150 |
Why?
|
Aged, 80 and over | 11 | 2022 | 58976 | 0.140 |
Why?
|
Risk Factors | 15 | 2019 | 74206 | 0.140 |
Why?
|
Sensitivity and Specificity | 6 | 2021 | 14666 | 0.140 |
Why?
|
Drug Therapy, Combination | 4 | 2018 | 6310 | 0.140 |
Why?
|
Moxibustion | 1 | 2016 | 8 | 0.140 |
Why?
|
Risk Assessment | 7 | 2019 | 23995 | 0.140 |
Why?
|
Anti-Bacterial Agents | 3 | 2022 | 7407 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1702 | 0.140 |
Why?
|
Trichuris | 1 | 2016 | 32 | 0.140 |
Why?
|
Focus Groups | 4 | 2021 | 1413 | 0.140 |
Why?
|
Cytokine Receptor Common beta Subunit | 1 | 2016 | 22 | 0.140 |
Why?
|
Hypnosis | 1 | 2016 | 82 | 0.130 |
Why?
|
Academic Medical Centers | 2 | 2017 | 2759 | 0.130 |
Why?
|
Enteric Nervous System | 2 | 2017 | 212 | 0.130 |
Why?
|
Plant Preparations | 1 | 2016 | 94 | 0.130 |
Why?
|
Chi-Square Distribution | 2 | 2014 | 3416 | 0.130 |
Why?
|
Radiography | 3 | 2017 | 6965 | 0.130 |
Why?
|
Herpes Zoster Vaccine | 1 | 2016 | 49 | 0.130 |
Why?
|
Neurofibromatosis 1 | 1 | 2001 | 561 | 0.130 |
Why?
|
Proctocolectomy, Restorative | 3 | 2016 | 190 | 0.130 |
Why?
|
Relaxation Therapy | 1 | 2016 | 181 | 0.120 |
Why?
|
Anastomosis, Surgical | 2 | 2016 | 983 | 0.120 |
Why?
|
Live Birth | 2 | 2016 | 511 | 0.120 |
Why?
|
Immunoglobulin Fab Fragments | 3 | 2011 | 445 | 0.120 |
Why?
|
Aged | 17 | 2022 | 169289 | 0.120 |
Why?
|
Education, Medical, Continuing | 1 | 2020 | 823 | 0.120 |
Why?
|
Diagnosis-Related Groups | 1 | 2016 | 449 | 0.120 |
Why?
|
Ileostomy | 1 | 2015 | 121 | 0.120 |
Why?
|
Integrins | 1 | 2019 | 834 | 0.120 |
Why?
|
Pregnancy | 6 | 2017 | 29874 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 787 | 0.120 |
Why?
|
Jews | 1 | 2016 | 356 | 0.120 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2014 | 84 | 0.120 |
Why?
|
Government Regulation | 1 | 2019 | 524 | 0.120 |
Why?
|
Frameshift Mutation | 1 | 2016 | 392 | 0.120 |
Why?
|
Needs Assessment | 1 | 2020 | 1139 | 0.120 |
Why?
|
Logistic Models | 3 | 2015 | 13255 | 0.120 |
Why?
|
Boston | 3 | 2016 | 9326 | 0.110 |
Why?
|
Infection Control | 1 | 2021 | 981 | 0.110 |
Why?
|
Ileum | 1 | 2016 | 557 | 0.110 |
Why?
|
Follicle Stimulating Hormone | 1 | 2016 | 726 | 0.110 |
Why?
|
Integrin alpha4 | 1 | 2013 | 87 | 0.110 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26125 | 0.110 |
Why?
|
Patient Compliance | 2 | 2014 | 2690 | 0.110 |
Why?
|
Mind-Body Therapies | 1 | 2016 | 279 | 0.110 |
Why?
|
Lymphoma | 2 | 2021 | 1901 | 0.110 |
Why?
|
Public Health Practice | 1 | 2015 | 219 | 0.110 |
Why?
|
ROC Curve | 2 | 2018 | 3579 | 0.110 |
Why?
|
Adenosine Triphosphatases | 1 | 2017 | 835 | 0.110 |
Why?
|
Ganciclovir | 1 | 2013 | 252 | 0.110 |
Why?
|
Immunoglobulin G | 2 | 2016 | 4544 | 0.110 |
Why?
|
Salicylic Acid | 1 | 2013 | 62 | 0.100 |
Why?
|
Secondary Prevention | 4 | 2013 | 1475 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 891 | 0.100 |
Why?
|
Yoga | 1 | 2016 | 281 | 0.100 |
Why?
|
Injections, Subcutaneous | 2 | 2024 | 681 | 0.100 |
Why?
|
Self Report | 5 | 2015 | 3724 | 0.100 |
Why?
|
Drug Administration Schedule | 2 | 2018 | 4853 | 0.100 |
Why?
|
Child | 8 | 2023 | 80153 | 0.100 |
Why?
|
Leukocytes, Mononuclear | 3 | 2016 | 1844 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1125 | 0.100 |
Why?
|
Acupuncture Therapy | 1 | 2016 | 486 | 0.100 |
Why?
|
Autoantibodies | 1 | 2021 | 2116 | 0.100 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2014 | 344 | 0.100 |
Why?
|
Histocytochemistry | 1 | 2013 | 698 | 0.100 |
Why?
|
Chronic Disease | 3 | 2021 | 9318 | 0.100 |
Why?
|
Double-Balloon Enteroscopy | 1 | 2011 | 7 | 0.100 |
Why?
|
Lectins | 1 | 2013 | 491 | 0.100 |
Why?
|
Polyradiculopathy | 1 | 2011 | 23 | 0.100 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 415 | 0.100 |
Why?
|
Multivariate Analysis | 2 | 2015 | 12059 | 0.100 |
Why?
|
Hematocrit | 1 | 2013 | 623 | 0.100 |
Why?
|
5'-Nucleotidase | 1 | 2012 | 161 | 0.100 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2012 | 357 | 0.090 |
Why?
|
Osteoarthritis, Hip | 1 | 2015 | 409 | 0.090 |
Why?
|
Placebos | 3 | 2024 | 1667 | 0.090 |
Why?
|
Meningitis, Viral | 1 | 2011 | 50 | 0.090 |
Why?
|
Polyethylene Glycols | 3 | 2011 | 1189 | 0.090 |
Why?
|
Purines | 1 | 2014 | 607 | 0.090 |
Why?
|
Chickenpox Vaccine | 1 | 2011 | 40 | 0.090 |
Why?
|
DNA, Viral | 1 | 2018 | 2202 | 0.090 |
Why?
|
Tuberculin Test | 1 | 2011 | 206 | 0.090 |
Why?
|
Abdominal Pain | 1 | 2017 | 1071 | 0.090 |
Why?
|
Models, Organizational | 1 | 2014 | 546 | 0.090 |
Why?
|
Tissue Distribution | 1 | 2014 | 2265 | 0.090 |
Why?
|
Reproducibility of Results | 4 | 2023 | 20098 | 0.090 |
Why?
|
Acyclovir | 1 | 2011 | 268 | 0.090 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2011 | 72 | 0.090 |
Why?
|
Patient Admission | 1 | 2018 | 1367 | 0.090 |
Why?
|
Hematologic Diseases | 1 | 2014 | 496 | 0.090 |
Why?
|
Steroids | 1 | 2015 | 929 | 0.090 |
Why?
|
Inflammation | 5 | 2014 | 10773 | 0.090 |
Why?
|
Self Efficacy | 1 | 2014 | 638 | 0.090 |
Why?
|
Program Development | 1 | 2016 | 1297 | 0.090 |
Why?
|
Mycobacterium | 1 | 2011 | 251 | 0.090 |
Why?
|
Piperidines | 1 | 2018 | 1656 | 0.080 |
Why?
|
Antiviral Agents | 2 | 2013 | 3060 | 0.080 |
Why?
|
Length of Stay | 2 | 2015 | 6425 | 0.080 |
Why?
|
Exercise Therapy | 1 | 2016 | 929 | 0.080 |
Why?
|
Graft vs Host Disease | 1 | 2022 | 3029 | 0.080 |
Why?
|
Case-Control Studies | 6 | 2017 | 22176 | 0.080 |
Why?
|
Infant, Low Birth Weight | 1 | 2013 | 870 | 0.070 |
Why?
|
Enterobacteriaceae Infections | 1 | 2010 | 188 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2013 | 1380 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6484 | 0.070 |
Why?
|
Hypothalamic Hormones | 1 | 2008 | 145 | 0.070 |
Why?
|
Pituitary Hormones | 1 | 2008 | 182 | 0.070 |
Why?
|
Polysaccharides | 1 | 2014 | 1014 | 0.070 |
Why?
|
Mice, Inbred NOD | 2 | 2022 | 1827 | 0.070 |
Why?
|
Plants, Medicinal | 1 | 2007 | 165 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2021 | 12341 | 0.070 |
Why?
|
Qualitative Research | 2 | 2015 | 3023 | 0.070 |
Why?
|
Receptors, Corticotropin-Releasing Hormone | 1 | 2007 | 89 | 0.070 |
Why?
|
Acute Disease | 2 | 2009 | 7237 | 0.070 |
Why?
|
Immune Tolerance | 2 | 2014 | 2303 | 0.070 |
Why?
|
Heparin | 1 | 2014 | 1634 | 0.070 |
Why?
|
Dietary Supplements | 2 | 2016 | 3415 | 0.070 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2020 | 3080 | 0.070 |
Why?
|
Melanins | 1 | 2008 | 290 | 0.070 |
Why?
|
Pyrimidines | 1 | 2018 | 3028 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1421 | 0.070 |
Why?
|
Forecasting | 2 | 2022 | 2928 | 0.070 |
Why?
|
Immunologic Memory | 1 | 2012 | 1359 | 0.060 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 2007 | 361 | 0.060 |
Why?
|
Phytotherapy | 1 | 2007 | 296 | 0.060 |
Why?
|
Postoperative Complications | 3 | 2015 | 15631 | 0.060 |
Why?
|
Abdomen | 1 | 2011 | 1128 | 0.060 |
Why?
|
Osteoarthritis, Knee | 1 | 2015 | 1234 | 0.060 |
Why?
|
Antibodies, Viral | 1 | 2016 | 3156 | 0.060 |
Why?
|
Intestinal Absorption | 1 | 2006 | 400 | 0.060 |
Why?
|
Comorbidity | 1 | 2019 | 10508 | 0.060 |
Why?
|
Clinical Competence | 1 | 2020 | 4792 | 0.060 |
Why?
|
Premedication | 1 | 2005 | 246 | 0.060 |
Why?
|
Antibiotic Prophylaxis | 1 | 2010 | 636 | 0.060 |
Why?
|
Biopsy | 2 | 2013 | 6766 | 0.060 |
Why?
|
Vitamin D Deficiency | 1 | 2014 | 1388 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1909 | 0.060 |
Why?
|
Interleukin-8 | 3 | 2016 | 695 | 0.060 |
Why?
|
Parkinson Disease | 1 | 2018 | 2877 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2014 | 1666 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2850 | 0.050 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2014 | 4369 | 0.050 |
Why?
|
Placebo Effect | 1 | 2007 | 518 | 0.050 |
Why?
|
Drug Resistance | 1 | 2009 | 1596 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8224 | 0.050 |
Why?
|
Psoriasis | 1 | 2011 | 950 | 0.050 |
Why?
|
Adaptation, Psychological | 1 | 2014 | 2629 | 0.050 |
Why?
|
Phosphoglycerate Kinase | 1 | 2022 | 66 | 0.050 |
Why?
|
Fructose-Bisphosphate Aldolase | 1 | 2022 | 51 | 0.050 |
Why?
|
Metronidazole | 1 | 2004 | 232 | 0.050 |
Why?
|
Data Collection | 1 | 2012 | 3322 | 0.050 |
Why?
|
Genetic Variation | 1 | 2018 | 6567 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 3 | 2017 | 36426 | 0.050 |
Why?
|
Ciprofloxacin | 1 | 2004 | 312 | 0.050 |
Why?
|
Age Factors | 2 | 2016 | 18395 | 0.050 |
Why?
|
Benzene | 1 | 2022 | 106 | 0.050 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12690 | 0.050 |
Why?
|
Immunity, Mucosal | 1 | 2004 | 483 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2781 | 0.050 |
Why?
|
Pilot Projects | 1 | 2014 | 8631 | 0.050 |
Why?
|
Video Recording | 1 | 2006 | 966 | 0.050 |
Why?
|
Formularies as Topic | 1 | 2021 | 94 | 0.050 |
Why?
|
Chemoprevention | 1 | 2003 | 326 | 0.050 |
Why?
|
Budesonide | 1 | 2022 | 157 | 0.050 |
Why?
|
Bilirubin | 1 | 2022 | 436 | 0.040 |
Why?
|
Antibody Formation | 1 | 2005 | 1395 | 0.040 |
Why?
|
Premature Birth | 1 | 2013 | 1782 | 0.040 |
Why?
|
United States | 3 | 2019 | 72334 | 0.040 |
Why?
|
Carcinoma, Papillary | 1 | 2006 | 785 | 0.040 |
Why?
|
Vitamin D | 1 | 2014 | 3303 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11742 | 0.040 |
Why?
|
Pharmaceutical Services | 1 | 2021 | 141 | 0.040 |
Why?
|
Social Support | 1 | 2009 | 2171 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5972 | 0.040 |
Why?
|
Regression Analysis | 1 | 2009 | 6343 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 1722 | 0.040 |
Why?
|
Area Under Curve | 2 | 2014 | 1638 | 0.040 |
Why?
|
Interleukin-17 | 2 | 2015 | 912 | 0.040 |
Why?
|
Immunoglobulin E | 1 | 2005 | 1502 | 0.040 |
Why?
|
Animals | 8 | 2022 | 168459 | 0.040 |
Why?
|
Biomedical Research | 1 | 2014 | 3429 | 0.040 |
Why?
|
Health Personnel | 1 | 2012 | 3335 | 0.040 |
Why?
|
Body Mass Index | 1 | 2016 | 12953 | 0.040 |
Why?
|
Anaphylaxis | 1 | 2005 | 757 | 0.040 |
Why?
|
Intestines | 3 | 2016 | 1909 | 0.040 |
Why?
|
Feces | 1 | 2024 | 1497 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2018 | 17904 | 0.040 |
Why?
|
Patient Selection | 1 | 2009 | 4244 | 0.040 |
Why?
|
Interleukin-10 | 1 | 2022 | 1175 | 0.030 |
Why?
|
Mice | 7 | 2022 | 81525 | 0.030 |
Why?
|
Causality | 1 | 2023 | 1242 | 0.030 |
Why?
|
Reference Standards | 1 | 2020 | 1003 | 0.030 |
Why?
|
Anti-Infective Agents | 1 | 2004 | 983 | 0.030 |
Why?
|
Dextran Sulfate | 1 | 2017 | 256 | 0.030 |
Why?
|
Health Care Surveys | 2 | 2014 | 2426 | 0.030 |
Why?
|
Administration, Rectal | 1 | 2015 | 70 | 0.030 |
Why?
|
Prevalence | 1 | 2013 | 15732 | 0.030 |
Why?
|
Methotrexate | 1 | 2022 | 1719 | 0.030 |
Why?
|
Referral and Consultation | 2 | 2020 | 3600 | 0.030 |
Why?
|
Herpesvirus 4, Human | 1 | 2021 | 1078 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2022 | 1616 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2007 | 3673 | 0.030 |
Why?
|
Open Reading Frames | 1 | 2018 | 815 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 857 | 0.030 |
Why?
|
Antibodies, Fungal | 1 | 2014 | 34 | 0.030 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2014 | 82 | 0.030 |
Why?
|
Porins | 1 | 2014 | 78 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2016 | 348 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2016 | 211 | 0.030 |
Why?
|
Salicylates | 1 | 2014 | 127 | 0.030 |
Why?
|
Sexual Behavior | 1 | 2024 | 2180 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3305 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2017 | 447 | 0.030 |
Why?
|
Motivation | 2 | 2014 | 2006 | 0.030 |
Why?
|
Infant | 2 | 2018 | 36192 | 0.030 |
Why?
|
Administration, Oral | 3 | 2006 | 4021 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5492 | 0.030 |
Why?
|
Life Style | 2 | 2015 | 3917 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2014 | 5869 | 0.030 |
Why?
|
Child, Preschool | 2 | 2018 | 42230 | 0.030 |
Why?
|
Cytoskeleton | 1 | 2018 | 1170 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2013 | 26198 | 0.030 |
Why?
|
Colorimetry | 1 | 2013 | 150 | 0.030 |
Why?
|
Thyroid Neoplasms | 1 | 2006 | 2332 | 0.030 |
Why?
|
Probability | 2 | 2009 | 2477 | 0.030 |
Why?
|
Anemia, Sickle Cell | 1 | 2001 | 1063 | 0.030 |
Why?
|
Quality of Life | 2 | 2014 | 13367 | 0.020 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2014 | 289 | 0.020 |
Why?
|
Serologic Tests | 1 | 2014 | 381 | 0.020 |
Why?
|
Pregnancy Rate | 1 | 2014 | 648 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2007 | 8002 | 0.020 |
Why?
|
Specialization | 1 | 2016 | 778 | 0.020 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2014 | 406 | 0.020 |
Why?
|
GPI-Linked Proteins | 1 | 2012 | 469 | 0.020 |
Why?
|
Gene Frequency | 1 | 2018 | 3606 | 0.020 |
Why?
|
Interdisciplinary Communication | 1 | 2016 | 931 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2568 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2014 | 871 | 0.020 |
Why?
|
Interprofessional Relations | 1 | 2016 | 990 | 0.020 |
Why?
|
Autophagy | 1 | 2018 | 1326 | 0.020 |
Why?
|
Decision Trees | 1 | 2011 | 504 | 0.020 |
Why?
|
Incidence | 2 | 2009 | 21353 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2021 | 3466 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2018 | 1745 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2013 | 983 | 0.020 |
Why?
|
Safety | 1 | 2013 | 1150 | 0.020 |
Why?
|
Trinitrobenzenesulfonic Acid | 1 | 2008 | 64 | 0.020 |
Why?
|
Drug Eruptions | 1 | 2011 | 335 | 0.020 |
Why?
|
Genetic Loci | 1 | 2018 | 2632 | 0.020 |
Why?
|
Reference Values | 2 | 2006 | 4920 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2014 | 1469 | 0.020 |
Why?
|
Phenotype | 2 | 2018 | 16591 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2012 | 1870 | 0.020 |
Why?
|
Urocortins | 1 | 2007 | 19 | 0.020 |
Why?
|
Monocytes | 1 | 2016 | 2570 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 4573 | 0.020 |
Why?
|
Alleles | 1 | 2018 | 6863 | 0.020 |
Why?
|
Postoperative Period | 1 | 2011 | 1813 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7396 | 0.020 |
Why?
|
Tandem Mass Spectrometry | 1 | 2013 | 1188 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6240 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2011 | 1258 | 0.020 |
Why?
|
Health Services Accessibility | 2 | 2014 | 5440 | 0.020 |
Why?
|
Enema | 1 | 2006 | 141 | 0.020 |
Why?
|
Enterotoxins | 1 | 2007 | 367 | 0.020 |
Why?
|
Attitude to Health | 1 | 2014 | 2025 | 0.020 |
Why?
|
Genome, Human | 1 | 2018 | 4425 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3778 | 0.010 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2012 | 1374 | 0.010 |
Why?
|
Sex Distribution | 1 | 2009 | 2281 | 0.010 |
Why?
|
Administration, Topical | 1 | 2006 | 704 | 0.010 |
Why?
|
Population Surveillance | 1 | 2014 | 2598 | 0.010 |
Why?
|
Communicable Diseases | 1 | 2012 | 875 | 0.010 |
Why?
|
Age Distribution | 1 | 2009 | 2880 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2014 | 2688 | 0.010 |
Why?
|
Macrophages | 1 | 2018 | 5769 | 0.010 |
Why?
|
Neuropeptides | 1 | 2008 | 944 | 0.010 |
Why?
|
Databases, Factual | 1 | 2018 | 7967 | 0.010 |
Why?
|
Confidence Intervals | 1 | 2008 | 2927 | 0.010 |
Why?
|
Signal Transduction | 2 | 2016 | 23445 | 0.010 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1246 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14414 | 0.010 |
Why?
|
Mice, SCID | 1 | 2007 | 2626 | 0.010 |
Why?
|
Sex Factors | 1 | 2015 | 10552 | 0.010 |
Why?
|
Pandemics | 1 | 2021 | 8654 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 2007 | 931 | 0.010 |
Why?
|
Quality Improvement | 1 | 2016 | 3801 | 0.010 |
Why?
|
Europe | 1 | 2008 | 3422 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2016 | 18965 | 0.010 |
Why?
|
Primary Health Care | 1 | 2016 | 4686 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22169 | 0.010 |
Why?
|
Transplantation, Heterologous | 1 | 2007 | 2385 | 0.010 |
Why?
|
NF-kappa B | 1 | 2007 | 2490 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2014 | 10445 | 0.010 |
Why?
|
Health Care Costs | 1 | 2011 | 3242 | 0.010 |
Why?
|
Pedigree | 1 | 2006 | 4542 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2013 | 9420 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2008 | 9539 | 0.010 |
Why?
|
Cell Line | 1 | 2007 | 15601 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2007 | 12795 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 11903 | 0.000 |
Why?
|